Lownes H E, Ives T J
Am J Obstet Gynecol. 1987 Aug;157(2):446-7. doi: 10.1016/s0002-9378(87)80191-6.
Treatment of arrhythmias during pregnancy is complicated by insufficient information on the effects of the drug on the fetus or possible alterations of the drug's pharmacodynamics in the mother. The use of mexiletine, a newly introduced antiarrhythmic agent, during the entire course of pregnancy and subsequent lactation is presented.